Literature DB >> 15297377

Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice.

Hideaki Moriwaki1, April Stempien-Otero, Michal Kremen, Aaron E Cozen, David A Dichek.   

Abstract

Several studies implicate elevated matrix metalloproteinase activity as a cause of cardiac fibrosis. However, it is unknown whether other proteases can also initiate cardiac fibrosis. Because absence of urokinase plasminogen activator (uPA) prevents development of cardiac fibrosis after experimental myocardial infarction in mice, we hypothesized that elevated activity of uPA or deficiency of the uPA inhibitor plasminogen activator inhibitor-1 (PAI-1) might cause cardiac fibrosis. We used mice with scavenger-receptor (SR)-directed, macrophage-targeted uPA overexpression (SR-uPA+/0 mice) and PAI-1 null mice to test these hypotheses. Our studies revealed that SR-uPA+/0 mice developed cardiac fibrosis beginning between 5 and 10 weeks of age. Fibrosis was preceded by cardiac macrophage accumulation, implicating uPA-secreting macrophages as important contributors to development of fibrosis. A key role for uPA-secreting macrophages in development of cardiac fibrosis was supported by experiments in which recipients of bone marrow transplants from SR-uPA+/0 donors but not nontransgenic donors developed cardiac macrophage accumulation and fibrosis. SR-uPA+/0 mice and recipients of SR-uPA+/0 bone marrow had neither macrophage accumulation nor fibrosis in other major organs despite the presence of higher levels of uPA in these organs than in hearts. PAI-1 null mice but not congenic, age-matched controls also developed macrophage accumulation and fibrosis in hearts but not in other organs. We conclude: (1) either elevated macrophage uPA expression or PAI-1 deficiency is sufficient to cause cardiac macrophage accumulation and fibrosis; (2) macrophages are important contributors to the development of cardiac fibrosis; and (3) the heart is particularly sensitive to the effects of excess uPA activity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15297377     DOI: 10.1161/01.RES.0000141427.61023.f4

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  43 in total

1.  Aging and Cardiac Fibrosis.

Authors:  Anna Biernacka; Nikolaos G Frangogiannis
Journal:  Aging Dis       Date:  2011-04       Impact factor: 6.745

2.  Vitronectin-binding PAI-1 protects against the development of cardiac fibrosis through interaction with fibroblasts.

Authors:  Jianyong Zhong; Hai-Chun Yang; Valentina Kon; Agnes B Fogo; Daniel A Lawrence; Ji Ma
Journal:  Lab Invest       Date:  2014-03-31       Impact factor: 5.662

Review 3.  Matricellular proteins in cardiac adaptation and disease.

Authors:  Nikolaos G Frangogiannis
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

4.  Binding of anti-SSA antibodies to apoptotic fetal cardiocytes stimulates urokinase plasminogen activator (uPA)/uPA receptor-dependent activation of TGF-β and potentiates fibrosis.

Authors:  Paraskevi Briassouli; Daniel Rifkin; Robert M Clancy; Jill P Buyon
Journal:  J Immunol       Date:  2011-10-17       Impact factor: 5.422

5.  Plasminogen activator inhibitor 1, fibroblast apoptosis resistance, and aging-related susceptibility to lung fibrosis.

Authors:  Wen-Tan Huang; Hasina Akhter; Chunsun Jiang; Mark MacEwen; Qiang Ding; Veena Antony; Victor John Thannickal; Rui-Ming Liu
Journal:  Exp Gerontol       Date:  2014-11-28       Impact factor: 4.032

6.  The role of macrophage-derived urokinase plasminogen activator in myocardial infarct repair: urokinase attenuates ventricular remodeling.

Authors:  Elina Minami; Chiara Castellani; Laura Malchodi; Jennifer Deem; Kate Bertko; Jessica Meznarich; Monja Dishmon; Charles E Murry; April Stempien-Otero
Journal:  J Mol Cell Cardiol       Date:  2010-04-07       Impact factor: 5.000

7.  Plasmin inhibition increases MMP-9 activity and decreases vein wall stiffness during venous thrombosis resolution.

Authors:  Nicholas A Dewyer; Vikram Sood; Erin M Lynch; Catherine E Luke; Gilbert R Upchurch; Thomas W Wakefield; Steven Kunkel; Peter K Henke
Journal:  J Surg Res       Date:  2007-06-14       Impact factor: 2.192

8.  Plasminogen activator inhibitor-1 (PAI-1) is cardioprotective in mice by maintaining microvascular integrity and cardiac architecture.

Authors:  Zhi Xu; Francis J Castellino; Victoria A Ploplis
Journal:  Blood       Date:  2009-12-15       Impact factor: 22.113

9.  Cross-sectional relations of multiple biomarkers representing distinct biological pathways to plasma markers of collagen metabolism in the community.

Authors:  Jacob Joseph; Michael J Pencina; Thomas J Wang; Laura Hayes; Geoffrey H Tofler; Paul Jacques; Jacob Selhub; Daniel Levy; Ralph B D'Agostino; Emelia J Benjamin; Ramachandran S Vasan
Journal:  J Hypertens       Date:  2009-06       Impact factor: 4.844

10.  A central role of plasmin in cardiac injury initiated by fetal exposure to maternal anti-Ro autoantibodies.

Authors:  Paraskevi Briassouli; Marc K Halushka; Joanne H Reed; Yair Molad; Karen Fox-Talbot; Lucas Buyon; Edwin Guzman; Achiau Ludomirsky; Robert M Clancy; Jill P Buyon
Journal:  Rheumatology (Oxford)       Date:  2013-04-18       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.